Literature DB >> 20880257

The soluble form of urokinase receptor promotes angiogenesis through its Ser⁸⁸-Arg-Ser-Arg-Tyr⁹² chemotactic sequence.

K Bifulco1, I Longanesi-Cattani, M Gala, G DI Carluccio, M T Masucci, V Pavone, L Lista, C Arra, M P Stoppelli, M V Carriero.   

Abstract

BACKGROUND: The urokinase plasminogen activator receptor (u-PAR) focuses the proteolytic activity of the urokinase plasminogen activator (u-PA) on the endothelial cell surface, thus promoting angiogenesis in a protease-dependent manner. The u-PAR may exist in a glycophosphatidylinositol-anchored and in a soluble form (soluble u-PAR [Su-PAR]), both including the chemotactic Ser⁸⁸ -Arg-Ser-Arg-Tyr⁹² internal sequence.
OBJECTIVE: To investigate whether Su-PAR may trigger endothelial cell signaling leading to new vessel formation through its chemotactic Ser⁸⁸ -Arg-Ser-Arg-Tyr⁹² sequence. METHODS AND
RESULTS: In this study, the formation of vascular-like structures by human umbilical vein endothelial cells was assessed by using a matrigel basement membrane preparation. First, we found that Su-PAR protein promotes the formation of cord-like structures, and that this ability is retained by the isolated Ser(88) -Arg-Ser-Arg-Tyr⁹² chemotactic sequence, the maximal effect being reached at 10 nmol L⁻¹ SRSRY peptide (SRSRY). This effect is mediated by the α(v) β₃ vitronectin receptor, is independent of u-PA proteolytic activity, and involves the internalization of the G-protein-coupled formyl-peptide receptor in endothelial cells. Furthermore, exposure of human saphenous vein rings to Su-PAR or SRSRY leads to a remarkable degree of sprouting. Finally, we show that Su-PAR and SRSRY promote a marked response in angioreactors implanted into the dorsal flank of nude mice, retaining 91% and 66%, respectively, of the angiogenic response generated by a mixture of vascular endothelial growth factor and fibroblast growth factor type 2.
CONCLUSIONS: Our results show a new protease-independent activity of Su-PAR that stimulates in vivo angiogenesis through its Ser⁸⁸ -Arg-Ser-Arg-Tyr⁹² chemotactic sequence.
© 2010 International Society on Thrombosis and Haemostasis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20880257     DOI: 10.1111/j.1538-7836.2010.04075.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  16 in total

1.  Roles of different IRES-dependent FGF2 isoforms in the acquisition of the major aggressive features of human metastatic melanoma.

Authors:  Elena Andreucci; Francesca Bianchini; Alessio Biagioni; Mario Del Rosso; Laura Papucci; Nicola Schiavone; Lucia Magnelli
Journal:  J Mol Med (Berl)       Date:  2016-08-24       Impact factor: 4.599

Review 2.  The Expanding Role of Biomarkers in Diagnosing Infection in Total Joint Arthroplasty: A Review of Current Literature.

Authors:  Ardalan Sayan; Adam Kopiec; Alisina Shahi; Madhav Chowdhry; Matthew Bullock; Ali Oliashirazi
Journal:  Arch Bone Jt Surg       Date:  2021-01

3.  Domain 2 of uPAR regulates single-chain urokinase-mediated angiogenesis through β1-integrin and VEGFR2.

Authors:  Gretchen A Larusch; Alona Merkulova; Fakhri Mahdi; Zia Shariat-Madar; Robert G Sitrin; Douglas B Cines; Alvin H Schmaier
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-05-24       Impact factor: 4.733

4.  Preclinical evaluation of the urokinase receptor-derived peptide UPARANT as an anti-inflammatory drug.

Authors:  Serena Boccella; Elisabetta Panza; Liliana Lista; Carmela Belardo; Angela Ianaro; Mario De Rosa; Vito de Novellis; Vincenzo Pavone
Journal:  Inflamm Res       Date:  2017-04-29       Impact factor: 4.575

5.  CRISPR/Cas9 uPAR Gene Knockout Results in Tumor Growth Inhibition, EGFR Downregulation and Induction of Stemness Markers in Melanoma and Colon Carcinoma Cell Lines.

Authors:  Alessio Biagioni; Anastasia Chillà; Mario Del Rosso; Gabriella Fibbi; Francesca Scavone; Elena Andreucci; Silvia Peppicelli; Francesca Bianchini; Lido Calorini; Anna Li Santi; Pia Ragno; Francesca Margheri; Anna Laurenzana
Journal:  Front Oncol       Date:  2021-05-14       Impact factor: 6.244

6.  Involvement of the soluble urokinase receptor in chondrosarcoma cell mobilization.

Authors:  Katia Bifulco; Immacolata Longanesi-Cattani; Maria Teresa Masucci; Annarosaria De Chiara; Flavio Fazioli; Gioconda Di Carluccio; Giuseppe Pirozzi; Michele Gallo; Antonello La Rocca; Gaetano Apice; Gaetano Rocco; Maria Vincenza Carriero
Journal:  Sarcoma       Date:  2010-12-30

7.  Cyclization of the urokinase receptor-derived ser-arg-ser-arg-tyr Peptide generates a potent inhibitor of trans-endothelial migration of monocytes.

Authors:  Ali Munaim Yousif; Michele Minopoli; Katia Bifulco; Vincenzo Ingangi; Gioconda Di Carluccio; Francesco Merlino; Maria Letizia Motti; Paolo Grieco; Maria Vincenza Carriero
Journal:  PLoS One       Date:  2015-05-04       Impact factor: 3.240

8.  Urokinase receptor promotes ovarian cancer cell dissemination through its 84-95 sequence.

Authors:  Katia Bifulco; Giuseppina Votta; Vincenzo Ingangi; Gioconda Di Carluccio; Domenica Rea; Simona Losito; Nunzia Montuori; Pia Ragno; Maria Patrizia Stoppelli; Claudio Arra; Maria Vincenza Carriero
Journal:  Oncotarget       Date:  2014-06-30

9.  Single amino acid substitutions in the chemotactic sequence of urokinase receptor modulate cell migration and invasion.

Authors:  Katia Bifulco; Immacolata Longanesi-Cattani; Paola Franco; Vincenzo Pavone; Pietro Mugione; Gioconda Di Carluccio; Maria Teresa Masucci; Claudio Arra; Giuseppe Pirozzi; Maria Patrizia Stoppelli; Maria Vincenza Carriero
Journal:  PLoS One       Date:  2012-09-25       Impact factor: 3.240

10.  Targeting the cross-talk between Urokinase receptor and Formyl peptide receptor type 1 to prevent invasion and trans-endothelial migration of melanoma cells.

Authors:  Concetta Ragone; Michele Minopoli; Vincenzo Ingangi; Giovanni Botti; Federica Fratangelo; Antonello Pessi; Maria Patrizia Stoppelli; Paolo Antonio Ascierto; Gennaro Ciliberto; Maria Letizia Motti; Maria Vincenza Carriero
Journal:  J Exp Clin Cancer Res       Date:  2017-12-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.